See more : Hotel Chocolat Group plc (HCHOF) Income Statement Analysis – Financial Results
Complete financial analysis of Takara Bio Inc. (4974.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Takara Bio Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Phol Dhanya Public Company Limited (PHOL.BK) Income Statement Analysis – Financial Results
- Companhia Brasileira de Alumínio (CBAV3.SA) Income Statement Analysis – Financial Results
- MicroBase Technology Corp. (3184.TWO) Income Statement Analysis – Financial Results
- Pricer AB (publ) (0H38.L) Income Statement Analysis – Financial Results
- Fuji Furukawa Engineering & Construction Co.Ltd. (1775.T) Income Statement Analysis – Financial Results
Takara Bio Inc. (4974.T)
About Takara Bio Inc.
Takara Bio Inc., together with its subsidiaries, operates as a biotechnology company in Japan, the United States, China, other Asia, Europe, and internationally. The company operates through Bioindustry and Gene Therapy segments. It develops research reagents and scientific instruments; and provides contract development and manufacturing organization (CDMO) services for academic and corporate life sciences research and development. The company's CDMO services include contract service for developing regenerative medicine products; related services, such as quality and safety testing, and cell banking; and contract services for supporting genetic analysis and testing comprising human genome sequence analysis, analysis of cancerrelated genes, and intestinal flora analysis, as well as support services for genetic engineering research, such as genome editing using the latest technologies and equipment. It also engages in the development and commercialization of various gene therapies, including oncolytic virus utilizing Canerpaturev, which is an attenuated strain of the herpes simplex virus type 1 that exhibits antitumor activity upon local injection into a tumor due to tumor lysis; siTCR gene therapy, which is in Phase I/II clinical trials for the treatment of synovial sarcoma; and CD19 chimeric antigen receptors that is in Phase I/II clinical trial for the treatment of adult acute lymphoblastic leukemia. Additionally, the company offers RetroNectin for gene therapy. The company was founded in 2002 and is headquartered in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 43.51B | 78.14B | 67.70B | 46.09B | 34.57B | 35.84B | 32.31B | 29.38B | 29.73B | 25.97B | 23.91B | 20.56B | 19.58B | 18.74B | 19.33B | 18.91B | 20.28B | 20.98B | 16.53B | 13.69B |
| Cost of Revenue | 16.60B | 33.38B | 18.49B | 14.21B | 13.46B | 15.16B | 13.66B | 12.42B | 13.41B | 12.14B | 11.33B | 9.54B | 9.19B | 8.86B | 9.29B | 8.97B | 10.06B | 11.16B | 9.38B | 7.32B |
| Gross Profit | 26.91B | 44.77B | 49.21B | 31.87B | 21.11B | 20.69B | 18.66B | 16.95B | 16.32B | 13.83B | 12.57B | 11.02B | 10.38B | 9.88B | 10.04B | 9.94B | 10.22B | 9.82B | 7.16B | 6.37B |
| Gross Profit Ratio | 61.85% | 57.29% | 72.69% | 69.16% | 61.06% | 57.72% | 57.73% | 57.71% | 54.91% | 53.24% | 52.60% | 53.61% | 53.04% | 52.72% | 51.95% | 52.56% | 50.41% | 46.81% | 43.30% | 46.53% |
| Research & Development | 8.32B | 8.58B | 6.11B | 5.55B | 3.87B | 4.34B | 4.65B | 4.10B | 4.28B | 3.40B | 3.03B | 2.72B | 2.66B | 2.69B | 3.29B | 2.98B | 3.30B | 3.24B | 3.12B | 2.99B |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 68.00M | 72.00M | 112.00M | 102.00M | 95.00M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 703.00M | 729.00M | 854.00M | 971.00M | 903.00M | 985.00M | 963.00M | 941.00M | 962.00M | 969.00M | 1.15B | 1.12B | 1.34B | 1.64B | 1.28B |
| SG&A | 15.58B | 15.65B | 14.20B | 12.37B | 10.96B | 703.00M | 729.00M | 854.00M | 971.00M | 903.00M | 985.00M | 963.00M | 1.01B | 1.03B | 1.08B | 1.25B | 1.21B | 1.34B | 1.64B | 1.28B |
| Other Expenses | 0.00 | 144.00M | 166.00M | 116.00M | 100.00M | 141.00M | 242.00M | 314.00M | 466.00M | 339.00M | 189.00M | 189.00M | 219.00M | 129.00M | 150.00M | 98.00M | 156.00M | 242.00M | 197.00M | 158.00M |
| Operating Expenses | 23.91B | 24.22B | 20.31B | 17.92B | 14.83B | 15.22B | 15.10B | 13.75B | 13.65B | 11.52B | 10.62B | 9.33B | 5.61B | 5.70B | 6.28B | 6.18B | 6.59B | 6.85B | 6.12B | 5.36B |
| Cost & Expenses | 40.50B | 57.60B | 38.80B | 32.13B | 28.29B | 30.37B | 28.75B | 26.17B | 27.06B | 23.66B | 21.95B | 18.87B | 14.81B | 14.56B | 15.56B | 15.15B | 16.64B | 18.01B | 15.49B | 12.68B |
| Interest Income | 186.00M | 142.00M | 122.00M | 113.00M | 141.00M | 89.00M | 77.00M | 108.00M | 170.00M | 146.00M | 124.00M | 107.00M | 106.00M | 87.00M | 116.00M | 190.00M | 156.00M | 76.00M | 20.00M | 12.00M |
| Interest Expense | 23.00M | 24.00M | 23.00M | 24.00M | 7.00M | 0.00 | 19.00M | 2.00M | 2.00M | 11.00M | 7.00M | 7.00M | 4.00M | 7.00M | 9.00M | 11.00M | 6.00M | 5.00M | 17.00M | 21.00M |
| Depreciation & Amortization | 5.02B | 4.74B | 4.15B | 3.79B | 3.53B | 3.38B | 3.22B | 2.05B | 2.07B | 1.67B | 1.47B | 1.51B | 1.54B | 1.67B | 1.85B | 2.07B | 2.16B | 2.41B | 2.05B | 1.78B |
| EBITDA | 7.90B | 25.28B | 33.05B | 17.74B | 9.81B | 8.84B | 6.77B | 5.25B | 4.74B | 4.16B | 3.66B | 3.79B | 3.21B | 2.65B | 2.56B | 1.61B | 2.83B | 1.99B | 816.00M | 911.00M |
| EBITDA Ratio | 18.16% | 32.56% | 48.20% | 38.99% | 28.58% | 27.02% | 21.97% | 19.16% | 18.06% | 17.16% | 15.54% | 16.93% | 33.72% | 32.18% | 30.70% | 30.49% | 30.16% | 27.40% | 26.01% | 20.81% |
| Operating Income | 3.00B | 20.54B | 28.90B | 13.95B | 6.27B | 5.46B | 3.56B | 3.20B | 2.67B | 2.30B | 1.95B | 1.69B | 4.77B | 4.18B | 3.76B | 3.76B | 3.64B | 2.98B | 1.04B | 1.01B |
| Operating Income Ratio | 6.90% | 26.29% | 42.69% | 30.27% | 18.15% | 15.24% | 11.00% | 10.90% | 8.97% | 8.86% | 8.17% | 8.22% | 24.37% | 22.30% | 19.47% | 19.88% | 17.94% | 14.18% | 6.30% | 7.35% |
| Total Other Income/Expenses | -150.00M | 683.00M | -1.37B | -400.00M | -841.00M | -640.00M | -194.00M | -397.00M | 238.00M | 179.00M | 231.00M | 577.00M | 115.00M | -3.20B | -3.07B | -327.00M | -2.97B | 590.00M | -2.29B | -1.89B |
| Income Before Tax | 2.85B | 21.22B | 27.53B | 13.55B | 5.43B | 4.82B | 3.36B | 2.81B | 2.91B | 2.48B | 2.19B | 2.27B | 1.66B | 978.00M | 697.00M | 99.00M | 671.00M | 375.00M | -1.25B | -888.00M |
| Income Before Tax Ratio | 6.56% | 27.16% | 40.67% | 29.41% | 15.72% | 13.46% | 10.40% | 9.55% | 9.77% | 9.55% | 9.14% | 11.03% | 8.49% | 5.22% | 3.61% | 0.52% | 3.31% | 1.79% | -7.57% | -6.49% |
| Income Tax Expense | 1.34B | 5.18B | 7.62B | 3.97B | 1.60B | 1.15B | 1.02B | 1.45B | 1.57B | 1.52B | 726.00M | 809.00M | 631.00M | 361.00M | 107.00M | -545.00M | -17.00M | 92.00M | -149.00M | 444.00M |
| Net Income | 1.48B | 16.01B | 19.85B | 9.55B | 3.82B | 3.66B | 2.34B | 1.35B | 1.33B | 963.00M | 1.47B | 1.46B | 1.02B | 605.00M | 591.00M | 642.00M | 679.00M | 320.00M | -1.06B | -1.28B |
| Net Income Ratio | 3.40% | 20.49% | 29.32% | 20.72% | 11.05% | 10.20% | 7.23% | 4.60% | 4.49% | 3.71% | 6.15% | 7.11% | 5.23% | 3.23% | 3.06% | 3.39% | 3.35% | 1.53% | -6.40% | -9.37% |
| EPS | 12.29 | 132.97 | 164.84 | 79.28 | 31.72 | 30.37 | 19.39 | 11.24 | 11.08 | 8.01 | 12.50 | 12.94 | 9.06 | 5.37 | 5.24 | 5.70 | 6.03 | 2.86 | -9.94 | -13.70 |
| EPS Diluted | 12.29 | 132.97 | 164.84 | 79.28 | 31.72 | 30.37 | 19.39 | 11.24 | 11.08 | 8.01 | 12.45 | 12.89 | 9.06 | 5.37 | 5.23 | 5.68 | 5.98 | 2.86 | -9.94 | -13.70 |
| Weighted Avg Shares Out | 120.42M | 120.42M | 120.42M | 120.42M | 120.42M | 120.42M | 120.42M | 120.42M | 120.42M | 120.42M | 117.60M | 113.04M | 112.92M | 112.87M | 112.80M | 112.40M | 112.40M | 112.00M | 106.40M | 93.60M |
| Weighted Avg Shares Out (Dil) | 120.42M | 120.42M | 120.42M | 120.42M | 120.42M | 120.42M | 120.42M | 120.42M | 120.42M | 120.42M | 118.07M | 113.42M | 112.92M | 112.87M | 112.96M | 112.93M | 113.53M | 112.00M | 106.40M | 93.60M |
Source: https://incomestatements.info
Category: Stock Reports